Abstract:The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due to its potentially superior effects compared with protein inhibition. Recent advancements in the biotech and pharmaceutical sectors have led to the development of compounds that are currently in human trials, with some showing promising clinical results. However, the use of computational tools in TPD is still limited, as it has distinct characteristics compared with traditional computational drug design methods. TPD involves creating a ternary structure (protein-degrader-ligase) responsible for the biological function, such as ubiquitination and subsequent proteasomal degradation, which depends on the spatial orientation of the protein of interest (POI) relative to E2-loaded ubiquitin. Modeling this structure necessitates a unique blend of tools initially developed for small molecules (e.g., docking) and biologics (e.g., protein-protein interaction modeling). Additionally, degrader molecules, particularly heterobifunctional degraders, are generally larger than conventional small molecule drugs, leading to challenges in determining drug-like properties like solubility and permeability. Furthermore, the catalytic nature of TPD makes occupancy-based modeling insufficient. TPD consists of multiple interconnected yet distinct steps, such as POI binding, E3 ligase binding, ternary structure interactions, ubiquitination, and degradation, along with traditional small molecule properties. A comprehensive set of tools is needed to address the dynamic nature of the induced proximity ternary complex and its implications for ubiquitination. In this Perspective, we discuss the current state of computational tools for TPD. We start by describing the series of steps involved in the degradation process and the experimental methods used to characterize them. Then, we delve into a detailed analysis of the computational tools employed in TPD. We also present an integrative approach that has proven successful for degrader design and its impact on project decisions. Finally, we examine the future prospects of computational methods in TPD and the areas with the greatest potential for impact.

Innovative, combinatorial and high-throughput approaches to degrader synthesis

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development

Major Advances in Emerging Degrader Technologies.

[Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications]

Characterisation of high throughput screening outputs for small molecule degrader discovery

Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders

Degraders in epigenetic therapy: PROTACs and beyond

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Protein degraders push into novel target space

Targeted protein degradation: from mechanisms to clinic

Chemistries of bifunctional PROTAC degraders

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Recent advances in targeted protein degraders as potential therapeutic agents

Bivalent Ligands for Protein Degradation in Drug Discovery

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies

Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods

Advancing targeted protein degradation for cancer therapy

PROTACs: Great Opportunities for Academia and Industry (an Update from 2020 to 2021).

Chimera induced protein degradation: PROTACs and beyond

The Present and Future of Novel Protein Degradation Technology